Clinical Trial Update: A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SANGUINATE for treatment of vaso-occlusive crisis in adults with sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Vaso-occlusive Crisis

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Anemia, Sickle Cell | Phase 2 | Status: COMPLETED